Effects of positive end-expiratory pressure on oscillated flow rate during high-frequency chest compression.
OBJECTIVE
To investigate the effects of positive end-expiratory pressure (PEEP) on end-expiratory lung volume (EELV) and mean oscillated flow rate (VOSC) during high-frequency chest compression (HFCC) in normal subjects and patients with severe COPD.


METHODS
Comparative study.


METHODS
Pulmonary function and lung mechanics laboratory, University of Alberta Hospitals.


METHODS
Six normal subjects (five male; one female) and six patients with clinically stable COPD (five male; one female) with hypercapnia.


METHODS
A pneumatic vest system was operated at 10 Hz with a mean chest wall pressure of 16 cm H2O to provide the HFCC. A closed-circuit spirometer system permitted measurement of HFCC- and PEEP-induced changes in EELV that were expressed as per cent baseline functional residual capacity (FRC). An isothermic chamber connected near the mouthpiece permitted measurement of VOSC.


RESULTS
For the normal subjects, HFCC caused a significant decrease in EELV to 82.0% of FRC (p < or = 0.01) and the addition of 4.8+/-0.5 cm H2O of PEEP during HFCC increased EELV to 97.5% FRC. In the COPD patients, HFCC decreased EELV to 92.3% of FRC (p < or = 0.01), and the addition of 3.7+/-1.0 cm H2O of PEEP increased EELV to 98.4% FRC. For the normal subjects, increasing EELV to near FRC caused VOSC during expiration to increase 14.6% (p < or = 0.01), but there was no significant effect on VOSC during inspiration (5.1% increase). In the COPD patients, PEEP increased VOSC during both inspiration (30.5%) and expiration (57.0%) (both, p < or = 0.01).


CONCLUSIONS
Addition of a modest amount of PEEP during HFCC prevents the decrease in EELV and increases VOSC during both phases of spontaneous breathing in COPD patients. This higher VOSC during HFCC+PEEP may improve the effectiveness of HFCC in clearing mucus from the lungs of patients with airway disease.
Perry
R J
RJ
University of Alberta, Edmonton, Canada.
Man
G C
GC
Jones
R L
RL
D000328:Adult; D005260:Female; D005652:Functional Residual Capacity; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009079:Mucociliary Clearance; D011175:Positive-Pressure Respiration; D012129:Respiratory Function Tests; D012138:Respiratory Therapy